You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

c-myc

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

DLBCL Trial in Qingdao (Selinexor combined with Prednisone, Etoposide, and Lenalidomide)

Not yet recruiting
  • DLBCL
  • Selinexor combined with Prednisone, Etoposide, and Lenalidomide
  • Qingdao, Shandong, China
    the affiliated hospital of Qingdao University
Aug 18, 2022

High-grade B-cell Lymphoma, Burkitt Lymphoma, Lymphoma, B-Cell Trial in Busan, Seoul (Sepantronium Bromide)

Not yet recruiting
  • High-grade B-cell Lymphoma
  • +8 more
  • Sepantronium Bromide
  • Busan, Korea, Republic of
  • +5 more
Feb 27, 2022

C-myc Biomarker Study for Diabetic Foot Ulcers

Recruiting
  • Diabetes
  • +3 more
    • San Francisco, California
    • +5 more
    Mar 9, 2022

    Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma, Aggressive B-cell NHL Trial in Boston

    Not yet recruiting
    • Refractory Aggressive B-cell Lymphomas
    • +12 more
    • Boston, Massachusetts
    • +1 more
    Oct 13, 2022

    Recurrent DLBCL Activated B-Cell Type, Recurrent DLBCL Germinal Center B-Cell Type, Recurrent High Grade B-Cell Lymphoma With

    Recruiting
    • Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
    • +8 more
    • Biospecimen Collection
    • +3 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Mar 8, 2023

    Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma Trial in United States (EPOCH-R,

    Active, not recruiting
    Has Results
    • Burkitt Lymphoma
    • +2 more
    • La Jolla, California
    • +29 more
    Nov 2, 2021

    Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma

    Not yet recruiting
    • Double-Expressor Lymphoma
    • +3 more
    • Sacramento, California
      University of California Davis Comprehensive Cancer Center
    Oct 27, 2022

    Recurrent DLBCL, Recurrent DLBCL, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6

    Withdrawn
    • Recurrent Diffuse Large B-Cell Lymphoma
    • +9 more
    • Autologous Hematopoietic Stem Cell Transplantation
    • +5 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 11, 2023

    DLBCL, High Grade B-Cell Lymphoma w/MYC & BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma w/MYC, BCL2 & BCL6

    Recruiting
    • Diffuse Large B-Cell Lymphoma
    • +2 more
    • Tampa, Florida
    • +1 more
    Jan 12, 2022

    Ann Arbor Stage II DLBCL, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma Trial in Scottsdale,

    Recruiting
    • Ann Arbor Stage II Diffuse Large B-Cell Lymphoma
    • +13 more
    • Scottsdale, Arizona
    • +2 more
    Jun 1, 2022

    Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia Trial in Houston

    Recruiting
    • Recurrent Acute Lymphoblastic Leukemia
    • +10 more
    • Houston, Texas
      M D Anderson Cancer Center
    Sep 21, 2022

    Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate

    Recruiting
    • Aggressive Non-Hodgkin Lymphoma
    • +8 more
    • Polatuzumab Vedotin
    • +6 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 26, 2023

    Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Burkitt Lymphoma, DLBCL

    Active, not recruiting
    Has Results
    • Adult Burkitt Lymphoma
    • +4 more
    • Chicago, Illinois
    • +4 more
    Feb 17, 2022

    Gastrooesophageal Cancer Trial in Sutton (ibrutinib)

    Unknown status
    • Gastrooesophageal Cancer
    • Sutton, Surrey, United Kingdom
      The Royal Marsden NHS Trust
    Sep 17, 2019

    Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell

    Active, not recruiting
    • Adult Grade III Lymphomatoid Granulomatosis
    • +71 more
    • Chicago, Illinois
    • +5 more
    Oct 8, 2021

    Aggressive Non-Hodgkin Lymphoma, Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Ann Arbor Stage II

    Active, not recruiting
    • Aggressive Non-Hodgkin Lymphoma
    • +13 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    Aug 18, 2022

    Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent

    Recruiting
    • Clonal Cytopenia of Undetermined Significance
    • +6 more
    • Ascorbic Acid
    • +12 more
    • Scottsdale, Arizona
    • +4 more
    May 26, 2022

    Ann Arbor Stage III DLBCL, Ann Arbor Stage IIX (Bulky) DLBCL, Ann Arbor Stage IV DLBCL Trial in United States (drug, other,

    Suspended
    • Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
    • +20 more
    • Tucson, Arizona
    • +110 more
    Jan 31, 2023

    CNS Tumor, Solid Tumor Trial in Worldwide (Nivolumab and Entinostat)

    Recruiting
    • CNS Tumor
    • Solid Tumor
    • Nivolumab and Entinostat
    • Randwick, New South Wales, Australia
    • +13 more
    Nov 8, 2022

    Hepatocellular Carcinoma, Solid Tumor, Hepatocellular Carcinoma Non-resectable Trial in San Antonio (OTX-2002, Tyrosine kinase

    Not yet recruiting
    • Hepatocellular Carcinoma
    • +6 more
    • San Antonio, Texas
      Next Oncology
    Aug 9, 2022

    Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid

    Not yet recruiting
    • Recurrent Endometrial Carcinoma
    • +8 more
    • BET Bromodomain Inhibitor ZEN-3694
    • +7 more
    • (no location specified)
    Jul 15, 2023

    AIDS Related Lymphoma, AIDS-Associated Lymphoma Trial run by the NCI (Filgrastim, Rituximab, EPOCH)

    Completed
    • AIDS Related Lymphoma
    • AIDS-Associated Lymphoma
    • Filgrastim
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Jan 18, 2022

    Tissue Samples From Breast Cancer Who Were Treated on Clinical

    Completed
    • Breast Cancer
    • diagnostic laboratory biomarker analysis
    • (no location specified)
    Jul 1, 2019

    High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma, Recurrent DLBCL Trial in New Brunswick

    Withdrawn
    • High Grade B-Cell Lymphoma, Not Otherwise Specified
    • +6 more
    • New Brunswick, New Jersey
      Rutgers Cancer Institute of New Jersey
    Jun 12, 2020

    Solid Tumor Trial in Hangzhou (WBC100)

    Recruiting
    • Solid Tumor
    • Hangzhou, Zhejiang, China
      the First Affiliated Hospital, School of Medicine, Zhejiang Univ
    Jan 25, 2023